Immunological mechanisms in sarcoidosis

Clinical and Experimental Allergy

Volumn 31, Issue 4, 2001, Pages 543-554

  Conron, M ^a   Du Bois, R M ^a  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CELL ADHESION MOLECULE; CELL SURFACE MARKER; CORTICOSTEROID; CYTOKINE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; EOTAXIN; ETANERCEPT; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HERMES ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 1 ANTIBODY; INTERLEUKIN 1; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 6; INTERLEUKIN 8; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3; MACROPHAGE DERIVED CHEMOKINE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MONOCYTE CHEMOTACTIC PROTEIN 1; PADGEM PROTEIN; RANTES; T LYMPHOCYTE RECEPTOR; THROMBOCYTE FACTOR 4; TUMOR NECROSIS FACTOR ALPHA;

ANTIGEN PRESENTING CELL; APOPTOSIS; BERYLLIOSIS; CELL TYPE; CLINICAL FEATURE; CLINICAL TRIAL; CYTOKINE RELEASE; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE MARKER; DRUG EFFICACY; EFFECTOR CELL; FIBROBLAST; FIBROSIS; GEOGRAPHIC DISTRIBUTION; GRANULOMA; HUMAN; IMMUNOMODULATION; IMMUNOPATHOGENESIS; IMMUNOTHERAPY; KVEIM TEST; LUNG ALVEOLUS MACROPHAGE; LUNG LAVAGE; LUNG SARCOIDOSIS; LYMPHOCYTE CLONE; LYMPHOCYTE SUBPOPULATION; MYCOBACTERIOSIS; NONHUMAN; POLYMORPHONUCLEAR CELL; PRIORITY JOURNAL; PROGNOSIS; REGULATORY MECHANISM; REVIEW; T LYMPHOCYTE; TH1 CELL; TH2 CELL;

ANIMALS; DISEASE PROGRESSION; HUMANS; SARCOIDOSIS;

EID: 0035725549     PISSN: 09547894     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2222.2001.01116.x     Document Type: Review

References (95)

1. Forgesetzle untersuchungen über des multiple benigne sarkoid
2. Description of sarcoidosis. Report of the subcommittee on classification and definition
3. International study of pulmonary sarcoidosis in mass chest radiography
4. Non viable autologous bronchoalveolar lavage cell preparations induce intradermal epithelioid granulomas in sarcoidosis patients
5. Tlymphocytes that accumulate in the lung in sarcoidosis have evidence of recent stimulation of the T-cell antigen receptor
6. Sarcoidosis
7. Oligoclonal V gene usage by T lymphocytes in BAL fluid from sarcoidosis patients
8. T-cell receptor repertoire of T lymphocytes recovered from the lung and blood of patients with sarcoidosis
9. Superantigens: Mechanism of T-cell stimulation and role in immune response
10. HLA-DPB1 glutamate 69: A genetic marker of beryllium disease
11. Maintenance of alveolitis in patients with chronic beryllium disease by beryllium specific helper T-cells
12. Chronic beryllium disease: An immune response by restricted families of T-cells
13. Restricted usage of TCR V alpha/J alpha gene segments with different nucleotide but identical amino acid sequences in HLA-DR3 +ye sarcoidosis
14. T cell receptor V gene expression in HLA typed Japanese patients with sarcoidosis
15. Presence of mycobacterial DNA in sarcoidosis
16. Growth of acid fast forms from the blood of patients with sarcoidosis
17. Detection of Mycobacterial rRNA in sarcoidosis with liquid phase hybridisation
18. Human herpes virus 8 variants in sarcoid tissues
19. Detection of adenovirus DNA in pulmonary fibrosis using nested PCR
20. Skin reactions in sarcoid
21. The Kveim test in sarcoidosis
22. The Kveim test in sarcoidosis
23. AntiKveim monoclonal antibody - New monoclonal antibody reacting to epithelioid cells in sarcoid granulomas
24. Proliferating alveolar macrophages in BAL and lung function changes in interstitial lung disease
25. Alveolar macrophages in idiopathic pulmonary fibrosis display a more monocyte-like immunophenotype and an increased release of free oxygen radicals
26. Kinetics and characteristics of alveolar macrophages in the normal steady state
27. The excess number of peritoneal macrophages in GM-CSF transgenic mice are generated by local proliferation
28. Lung restricted activation of the alveolar macrophage/ monocyte system in pulmonary sarcoidosis
29. Release of interleukin-1 by alveolar macrophages of patients with active pulmonary sarcoidosis
30. Immunology and immunohistology of sarcoidosis
31. Spontaneous IL2 release of BAL cells in sarcoidosis is a co-determinator of prognosis
32. Sensitivity and specificity of BAL findings in sarcoidosis
33. Spontaneous release of IL-2 by lung T-cells in active pulmonary sarcoidosis
34. IFN-γ is spontaneously released by alveolar macrophages and T-lymphocytes in patients with pulmonary sarcoidosis
35. Pulmonary sarcoidosis: A disorder mediated by excess helper T-lymphocyte activity at sites of disease activity
36. Compartmentalized activation of the IL-2 gene by lung T-lymphocytes in active pulmonary sarcoidosis
37. T lymphocyte recruitment by IL-8
38. Role of IL-2 and IL-15 and their receptors in the development of T cell alveolitis in sarcoidosis
39. Production of the RANTES chemokine in delayed hypersensitivity reactions. Involvement of the macrophages and epithelial cells
40. Cytokines in sarcoidosis
41. Interleukin 16 and its function as CD4 ligand
42. Immunohistochemical analysis of sarcoid granulomas. Evaluation Ki67+ and IL-1 + cells
43. Sarcoidosis: Immunopathogenic concepts and their clinical application
44. Thl and Th2 responses regulate experimental lung granuloma formation
45. Thl/Th2 cell distribution in pulmonary sarcoidosis
46. BAL in pulmonary fibrosis: Comparison of cells obtained with lung biopsy and clinical features
47. Increased CD45RO expression on T lymphocytes in mediastinal lymph nodes and pulmonary lesions of patients with pulmonary sarcoidosis
48. Pulmonary immune cells in health and disease. Polymorphoneutrophils
49. Monokine production by hypersensitivity and foreign body type granuloma macrophages
50. Granuloma formation signifies a Thl cell profile
51. Enhanced expression of IL-12 associated with Thl cytokine profiles in active pulmonary sarcoidosis
52. Interleukin-8 and related chemotactic cytokines-CXC and CC chemokines
53. Role of GM-CSF in the regulation of alveolar macrophage proliferation and differentiation
54. Interferon-γ is necessary for the expression of hypersensitivity pneumonitis
55. Mycobacteria and schistosomal antigen-elicited granuloma formation in IFN-γ and IL-4 knockout mice
56. Expression of tumour necrosis factor-receptor superfamily members by lung T lymphocytes in interstitial lung disease
57. Sarcoidosis: TNFtx release from alveolar macrophages and serum levels of sIL-2R are prognostic markers
58. Fas and the act of lymphocyte maintenance
59. The proto-oncogene Bcl-2 and its role in regulating apoptosis
60. Prevention of apoptosis by Bcl-2: Release of cytochrome c from mitochondria blocked
61. Fibroblasts prevent apoptosis of IL-2 deprived T-cells without inducing proliferation: A selective effect on Bcl-XL expression
62. Cellular environments and apoptosis: Tissue microenvironments control activated cell death
63. C: A role for Thl and Th2 cytokines in the regulation of human monocyte apoptosis
64. Interleukin-15 protects from lethal apoptosis in vivo
65. IL-15, an immunomodulator of T-cell responses in intracellular infection
66. Erythema nodosum: Studies in aetiology and pathogenesis of 185 adult cases
67. Sarcoidosis: Epidemiology and prognosis. A 15 year European study
68. A worldwide review of sarcoidosis
69. Current concepts in the pathogenesis of sarcoidosis
70. Inflammatory and immunoregulatory roles of TGFβ
71. Anti-inflammatory cytokine release by alveolar macrophages in pulmonary sarcoidosis
72. Increased production and immunohistochemical localisation of TGF[3 in idiopathic fibrosis
73. Respiratory epithelial cell expression of transforming growth factor induces lung fibrosis in transgenic mice
74. Localisation of PDGF and IGF1 in the fibrotic lung
75. Cytokine binding proteins in the lung
76. A type 2 (Th-2 like) pattern of immune response predominates in the pulmonary interstitium of patients with cryptogenic fibrosing alveolitis
77. Increased expression of pro-inflammatory chemokines in BAL cells of patients with progressive pulmonary fibrosis and sarcoidosis
78. Cytokines in BAL fluid of patients with active pulmonary sarcoidosis
79. Evaluation of serum angiotensin converting enzyme (ACE) level in sarcoidosis
80. The specificity of serum angioconverting enzyme in sarcoidosis and other disease
81. Clinical value of ACE genotyping in diagnosis of sarcoidosis
82. Elevation of plasma-soluble tumour necrosis factor receptors (TNF-R) in sarcoidosis
83. Prognostic value of Ia+ T lymphocytes in BAL fluid in pulmonary sarcoidosis
84. Relation between immunocytological features of BAL fluid and clinical indices in sarcoidosis
85. The alveolitis of pulmonary sarcoidosis: Evaluation of natural history and alveolitis dependent on changes in lung function
86. Predictive value of BAL in pulmonary sarcoidosis
87. Predictive value of BAL T-cell subsets for the course of pulmonary sarcoidosis
88. Alveolar T-cell subsets and immunoglobulin concentrations in pulmonary sarcoidosis: Correlation with disease activity and effect of steroid treatment
89. A controlled trial of prednisolone treatment for sarcoidosis
90. Pulmonary sarcoidosis: A prospective evaluation of glucocorticoid therapy
91. Pulmonary sarcoidosis: Long term followup of the effects of steroid therapy
92. British thoracic society sarcoidosis study: Effects of longterm corticosteroid treatment
93. Phase IH trial of DMARD failing rheumatoid arthritis patients with TNF receptor p75 Fc fusion protein
94. A trial of etanercept, a recombinant tumour necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate